ClinicalTrials.gg
RecruitingNCT06897839ZELAUpdated Oct 9, 2026

Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD)

A Phase 2/3 interventional study of Air-sham and Zelpultide alfa in Bronchopulmonary Dysplasia, sponsored by Airway Therapeutics, Inc.. Recruiting at 49 sites in 8 countries. Open to participants aged 0 Minutes to 96 Hours. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Airway Therapeutics, Inc. · Phase 2/3, Interventional, and Prevention

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.
Updated Oct 9, 2026Site recruiting status changed1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
366
Allocation
Randomized
Ages
0 Minutes to 96 Hours
Sex
All
01

Study summary

This is a randomized, parallel-group, double-blind, placebo-controlled multicenter phase 2b/3 study with an adaptive seamless design.

The goal fo this study is to determine if an investigational drug, Zelpultide Alfa, can reduce the occurrence of Bronchopulmonary Dysplasia (BPD) in extremely premature babies.

The study comprises 2 parts:

  • Part 1: Phase 2b, dose selection and exploratory efficacy and safety.
  • Part 2: Phase 3, confirmatory efficacy and safety.

In Part 1, the study subjects will be randomized with a 1:1:1 allocation ratio to either :

  1. Standard of care + zelpultide alfa 4 mg/kg or,
  2. Standard of care + zelpultide alfa 6 mg/kg or,
  3. Standard of care + placebo (air-sham).

In Part 1, all three arms will be evaluated descriptively to support dose selection based on safety, tolerability, and exploratory efficacy signals. Upon completion of Part 1, the DSMC will recommend which Phase 2b dose ("selected dose") to progress into Part 2 to the Study Steering Committee, which will decide the dose for Part 2 (Phase 3). A sample size reassessment will be performed after Part 1 completion.

In Part 2, the selected dose of zelpultide alfa will be compared against placebo (air-sham) in a confirmatory analysis on the primary and key secondary endpoints. The study subjects will be randomized with a 1:1 allocation ratio to either:

  1. Standard of care + zelpultide alfa (selected dose from Part 1), or
  2. Standard of care + placebo (air-sham). The main objective in part 2 is to compare the efficacy of zelpultide alfa added to standard of care versus standard of care plus placebo (air-sham) in terms of incidence of grade 2 and grade 3 bronchopulmonary dysplasia (BPD) and death in neonates at high risk for developing BPD.

In both parts, treatment will be administered intratracheally. Participants will receive up to 7 administrations of zelpultide alfa at (4mg/kg or 6 mg/kg) or air-sham in 24 h intervals while the subjects are still intubated per standard of care.

02

Conditions studied

  • Bronchopulmonary Dysplasia

Keywords

  • BPD
  • Zelpultide alfa
  • AT-100
03

In context

Bronchopulmonary Dysplasia

362 studies on the registry are indexed under Bronchopulmonary Dysplasia; 84 are open to participants now.

This study's planned enrollment of 366 is above the median of 66 across 244 interventional studies indexed under Bronchopulmonary Dysplasia.

Browse Bronchopulmonary Dysplasia studies →

Lead sponsor

Airway Therapeutics, Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Minutes to 96 Hours
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Born between gestational age (GA) 22 0/7 to 27 6/7 weeks, inclusive.
  2. Received at least 1 dose of SOC-indicated animal-derived pulmonary surfactant treatment after birth.
  3. Intubated and on invasive mechanical ventilation per SOC.
  4. Able to receive the first dose of zelpultide alfa or air-sham at least 15 min after the surfactant administration but within 96 h of birth and within 48 h from the start of invasive mechanical ventilation. Subjects extubated and re-intubated after their pulmonary surfactant dose(s) are eligible as long as the inclusion criteria are met.
  5. and personal information authorization form signed by the subject's parent(s) or legal guardian(s).

Exclusion criteria

Exclusion Criteria:

  1. Birth weight \< 400 g or > 1,500 g.
  2. Major apparent congenital abnormalities impacting cardio and pulmonary function identified before randomization, such as, but not limited to:

    • Potter-like syndrome and any pulmonary congenital anomalies,
    • Clinically relevant congenital diaphragmatic hernia,
    • Omphalocele or gastroschisis, esophageal atresia,
    • Known or suspected cyanotic congenital heart disease (ie, tetralogy of fallot, transposition of the great arteries, etc).
  3. Active do no resuscitate (DNR) order in place.
  4. History of allergy or sensitivity to any surfactant or any component of zelpultide alfa.
  5. Concurrent enrollment in any clinical study that utilizes treatments ( medical products or devices) outside of SOC or participation in studies within the last 30 days (or 5 half-lives of an IMP) prior to birth (for the mother) or up to week 36 PMA.
  6. Any condition or situation that, in the Investigator's judgement, puts the neonate at significant risk, could confound the study results, or may interfere significantly with the neonate's participation in the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
366 participants (estimated)

Study arms

  • Experimental
    Zelpultide alfa 4 mg/kg plus standard of care

    In addition to the preterm neonate standard of care, the subjects randomized to this treatment arm will receive up to 7 administrations of zelpultide alfa at 4 mg/kg (birth weight) in 24 h intervals while the subjects are still intubated.

    Drug: Zelpultide alfa

  • Sham comparator
    Placebo (air-sham) plus standard of care

    In addition to the preterm neonate standard of care, approximately 1 mL of air drawn into a dosing syringe will be administered up to 7 times to neonate subjects randomized to the control (placebo) arm, following the same means and intervals as in the treatment arm.

    Other: Air-sham

  • Experimental
    Zelpultide alfa 6 mg/kg plus standard of care

    In addition to the preterm neonate standard of care, the subjects randomized to this treatment arm will receive up to 7 administrations of zelpultide alfa at 6 mg/kg (birth weight) in 24 h intervals while the subjects are still intubated.

    Drug: Zelpultide alfa

Interventions

  • OtherAir-sham

    Room air for intratracheal administration

  • Reconstituted Zelpultide alfa for intratracheal administration

    Also known as: AT-100, rhSP-D

06

What researchers measure

Primary outcomes

  1. Incidence of grade 2 or grade 3 Bronchopulmonary Dysplasia (BPD) or death

    BPD is defined and graded based on the classification according to Jensen et al., 2019 (2019 PMID: 30995069)

    Time frame: Week 36 Post Menstrual Age (PMA)

Secondary outcomes

  1. Ventilator-free days

    A ventilator-free day is defined as a natural calendar day without being on invasive mechanical ventilation (ie, invasive ventilation via ETT or tracheostomy); tracheostomy will be treated as all invasive ventilation.

    Time frame: From birth to 36 weeks Post Menstrual Age (PMA)

  2. Incidence of grade 2 or grade 3 Bronchopulmonary Dysplasia (BPD)

    Time frame: Week 36 Post Menstrual Age (PMA)

  3. Incidence of death

    Time frame: Week 36 Post Menstrual Age (PMA)

  4. Incidence of grade 2 or grade 3 Bronchopulmonary Dysplasia (BPD) or death assessed on 3 consecutive days at week 36 PMA

    BPD is defined and graded based on the classification according to Jensen et al., 2019 (2019 PMID: 30995069)

    Time frame: Week 36 Post Menstrual Age (PMA)

  5. The proportion of subjects with no Bronchopulmonary Dysplasia (BPD), grade 1, grade 2, or grade 3 BPD

    BPD is defined and graded based on the classification according to Jensen et al., 2019 (2019 PMID: 30995069)

    Time frame: Week 36 Post Menstrual Age (PMA)

  6. The proportion of subjects with no Bronchopulmonary Dysplasia (BPD), grade 1, grade 2, or grade 3 BPD assessed on 3 consecutive days at week 36 PMA

    BPD is defined and graded based on the classification according to Jensen et al., 2019 (2019 PMID: 30995069)

    Time frame: Week 36 Post Menstrual Age (PMA)

  7. Ventilator-free days

    A ventilator-free day is defined as a natural calendar day without being on invasive mechanical ventilation (ie, invasive ventilation via ETT or tracheostomy); tracheostomy will be treated as all invasive ventilation.

    Time frame: From birth to day 28 of life

  8. Total average days on supplemental oxygen

    Time frame: From birth to 36 Weeks Post Menstrual Age (PMA)

  9. Total average days on continuous positive airway pressure (CPAP) or high flow nasal cannula (HFNC)

    Time frame: From birth to week 36 Post Menstrual Age (PMA)

  10. Extubation rate

    Time frame: Study Day 7

  11. Average preductal oxygen saturation measured by oxygen saturation to fraction of inspired oxygen ratio (SF)

    Time frame: From Study Days 1 to 7

  12. Average preductal oxygen saturation measured by oxygen saturation index (OSI)

    Time frame: From Study Days 1 to 7

  13. Incidence of grade 2 or grade 3 Bronchopulmonary Dysplasia (BPD) or death

    BPD is defined and graded based on the classification according to Jensen et al., 2019 (2019 PMID: 30995069)

    Time frame: Week 40 Post Menstrual Age (PMA)

  14. Incidence of grade 2 or grade 3 Bronchopulmonary Dysplasia (BPD)

    BPD is defined and graded based on the classification according to Jensen et al., 2019 (2019 PMID: 30995069)

    Time frame: Week 40 Post Menstrual Age (PMA)

  15. The proportion of subjects with no Bronchopulmonary Dysplasia (BPD), grade 1, grade 2, or grade 3 BPD

    BPD is defined and graded based on the classification according to Jensen et al., 2019 (2019 PMID: 30995069)

    Time frame: Week 40 Post Menstrual Age (PMA)

  16. Incidence of grade 2 or grade 3 Bronchopulmonary Dysplasia (BPD) or death after excluding subjects with death at ≤ 14 days postnatal age

    BPD is defined and graded based on the classification according to Jensen et al., 2019 (2019 PMID: 30995069)

    Time frame: Week 36 and week 40 Post Menstrual Age (PMA)

  17. Ventilator-free days

    A ventilator-free day is defined as a natural calendar day without being on invasive mechanical ventilation (ie, invasive ventilation via ETT or tracheostomy); tracheostomy will be treated as all invasive ventilation.

    Time frame: From birth to week 40 Post Menstrual Age (PMA)

  18. Survival at 6, 12 and 24 months corrected age

    Time frame: 6, 12 and 24 month corrected age

  19. Average number of hospitalizations and days in hospital

    Time frame: 6 and 12 months corrected age

  20. Incidence of chronic respiratory morbidity

    Time frame: 12 month corrected age

  21. Incidence of neurodevelopmental disability among survivors

    Time frame: 24 months corrected age

  22. Severity and frequency of treatment-emergent adverse events (TEAEs) or treatment-emergent serious adverse events (TESAEs)

    Time frame: From start of treatment through week 36 Post Menstrual Age (PMA) or hospital discharge, whichever comes first

  23. Immunogenicity analysis

    Determination of anti-SP-D antibodies in blood at day 28 of life compared to baseline), assessed in a subset of 60 patients

    Time frame: Day 28 of life

07

Study locations

47 of 49 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Mar 2028, 37 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2025
First posted
Mar 27, 2025
StartActual
Feb 3, 2025
Primary completionEst.
Mar 31, 2028
CompletionEst.
Apr 30, 2030
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site removed. 2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • University Hospital in Krakow · Krakow, PolandNot yet recruiting→Recruiting
  • University Clinical Hospital No. 2 PUM · Szczecin, PolandNot yet recruiting→Recruiting
Show 1 removed
  • Cliniques Universitaires Saint-Luc · Brussels, Belgium
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    1 site removed. 2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • University Hospital in Krakow · Krakow, PolandNot yet recruiting→Recruiting
    • University Clinical Hospital No. 2 PUM · Szczecin, PolandNot yet recruiting→Recruiting
    Show 1 removed
    • Cliniques Universitaires Saint-Luc · Brussels, Belgium

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06897839
Lead sponsor
Airway Therapeutics, Inc.
Responsible party
Sponsor
First posted
Mar 27, 2025
Start date
Feb 3, 2025
Primary completion
Mar 31, 2028 (estimated)
Completion
Apr 30, 2030 (estimated)
Last update
Oct 9, 2026

Study contacts

Alan Wolk
Contact
info@airwaytherapeutics.com
513-770-9630

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zelpultide alfa

Start the discussion